相关实验视频
补充多可萨赫酸和阿尔茨海默病的认知衰退:一个随机试验
Joseph F Quinn1, Rema Raman, Ronald G Thomas
1Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA. quinnj@ohsu.edu
JAMA
|November 4, 2010
概括
补充多可萨赫萨酸 (DHA) 并没有减缓轻度至中度阿尔茨海默病患者的认知或功能衰退. 这项为期18个月的试验没有发现对认知得分或脑缩率有有益影响.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 老年学是一门学科.
背景情况:
- 多可萨赫萨酸 (DHA) 是一种在大脑中丰富的关键omega-3脂肪酸.
- 流行病学和动物研究表明,DHA可能会降低阿尔茨海默病的风险和病理.
- 在管理现有的阿尔茨海默病中补充DHA的作用仍在调查中.
研究的目的:
- 评估DHA补充剂在减缓阿尔茨海默病患者认知和功能衰退方面的疗效.
- 评估DHA对轻度至中度阿尔茨海默病患者脑缩率的影响.
主要方法:
- 一个随机,双盲,安慰剂控制的试验,涉及402名患有轻度至中度阿尔茨海默病的参与者.
- 参与者在18个月内每天接受2g藻类DHA或安慰剂.
- 认知功能 (ADAS-cog),功能状态 (CDR框的总和) 和大脑缩 (MRI) 是主要的结果指标.
主要成果:
- 补充DHA在减缓认知能力下降的速度方面没有显著的益处 (ADAS-cog分数).
- 通过CDR盒的总和来测量功能的下降,也没有受到DHA治疗的显著影响.
- 卷度MRI显示,DHA和安慰剂组之间脑缩率没有差异.
结论:
- 口服补充DHA似乎不会减缓轻度至中度阿尔茨海默病患者的认知或功能衰退.
- 这些发现不支持在这个人群中使用DHA作为阿尔茨海默病的治疗剂.
- 进一步的研究可能会探索在神经退行性疾病中用于DHA干预的不同剂量,持续时间或患者群体.
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.